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Abstract
The validation of biomarkers has become a key goal of translational biomedical research. The purpose of this article
is to discuss the role of biomarkers in the management of acute lung injury (ALI) and related research. Biomarkers
should be sensitive and specific indicators of clinically important processes and should change in a relevant
timeframe to affect recruitment to trials or clinical management. We do not believe that they necessarily need to
reflect pathogenic processes. We critically examined current strategies used to identify biomarkers and which,
owing to expedience, have been dominated by reanalysis of blood derived markers from large multicenter Phase 3
studies. Combining new and existing validated biomarkers with physiological and other data may add predictive
power and facilitate the development of important aids to research and therapy.
Introduction
The syndrome acute lung injury (ALI) and its more
severe counterpart acute respiratory distress syndrome
(ARDS) are defined by radiographic and physiological
changes that characterize patients with acute lung fail-
ure (Table 1) [1]. All age groups may be affected,
although the syndrome has a higher incidence and mor-
tality in older people. Across all ages the incidence is
approximately 200,000 cases per year in the United
States with a mortality of around 35% [2]. Survivors face
a long-term reduction in quality of life; for example,
only 54% of survivors were able to return to work 12
months after hospital discharge [3].
The validation of biomarkers, for use in clinical
trials and ultimately in practice, has become a central
tenet of translational biomedical research [4]. The
purpose of this article is to discuss the role of biomar-
kers in the management of ALI and related research.
We shall not present a state of the art review of the
field of all the biomarkers that have been investigated
in this field, excellent examples of which have been
produced recently [5,6]. Rather, we shall question cur-
rent strategies to identify biomarkers and whether
what has been achieved thus far has advanced the
field.
The natural history of acute lung injury
Regardless of the wide variety of insults that cause or
contribute to the development of ALI, the response of
the lung is largely stereotypic. A combination of tissue
injury and inflammation affecting the gas exchange sur-
face of the lung, the alveolar-capillary membrane, causes
high permeability pulmonary edema. The presence of a
protein-rich inflammatory exudate in the airspace
impairs surfactant function [7]. The resulting collapse
and consolidation of the lung causes profound hypoxe-
mia because inflammatory mediators induce changes in
the control of vascular tone that disable hypoxic pul-
monary vasoconstriction [8]. Loss of pulmonary capillary
surface area associated with localized lung destruction
and occlusion of the vascular bed by intravascular
thrombosis, increases the anatomical dead space, itself
associated with a poor outcome [9], giving rise to car-
bon dioxide retention. Host factors, both inherited
[10,11] and acquired, influence individual susceptibility,
(for example, excessive alcohol consumption predis-
poses, while diabetes mellitus protects) [12,13]. Precipi-
tating causes or risk factors, which often “hunt in
packs”, either affect the lung directly (pneumonia,
aspiration of stomach contents and thoracic trauma) or
cause ALI indirectly through a systemic inflammatory
response syndrome (SIRS) associated with multiple
organ dysfunction, exemplified by severe sepsis and
transfusion related ALI [14]. These causes, to a large
part, determine the initial clinical course and outcome,
but most patients subsequently require invasive
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mechanical ventilation in an intensive care unit to main-
tain adequate gas exchange and often other organ
supports.
While the development of pulmonary fibrosis in a
patient with ALI predicts the requirement for prolonged
respiratory support and a poor outcome [15], relatively
little is known about the processes that determine the
resolution of inflammation, injury and subsequent lung
repair [16]. The consecutive three-phase pathological
model of ALI (exudative, proliferative and fibrotic) is a
gross over-simplification. Fibrosis is evident histologi-
cally as early as a week after the onset of the disorder
[17] and procollagen III peptide, a precursor of collagen
synthesis, is elevated in the broncho-alveolar lavage
(BAL) fluid of ARDS patients at the time of tracheal
intubation [18]. Indeed, not only is the injured lung
known to be heterogeneously affected [19], it also seems
likely from the examination of lavage samples from
patients that these pathological processes coincide in the
same lung region [20]. Similarly, while several pro-
inflammatory mediators are also pro-fibrotic, distinct
patterns of gene expression are associated with acute
inflammation and fibrosis in the injured lung, suggesting
that fibrosis is not simply an inevitable consequence of
unresolved inflammation [21]. Indeed, current thinking
emphasizes the primary role of disordered epithelial
repair, which may be contributed to by repeated or per-
sistent injury and inflammation, in driving a pathological
fibrotic response [22].
Despite years of concerted effort and very many clini-
cal trials, a minority of which have been capable of pro-
ducing a definitive result, there are no treatments (as
opposed to modifications of organ support [23,24]) that
improve the outcome of patients with ALI [25]. What
has become evident, both in this field and in critical
care in general, is the extent and importance of iatro-
genic injury. Hence, half of ALI arises in patients who
were subjected to mechanical ventilation for another
reason: the four major culprits being mechanical ventila-
tion that targets normal blood gas parameters, transfu-
sion of blood products, excessive fluid resuscitation and
hospital acquired pneumonia (Figure 1) [26-29]. Accord-
ingly, recent epidemiological evidence suggests that tar-
geting hospital acquired injury can halve the incidence
of ARDS despite an increase in patients’ severity of ill-
ness, the number of comorbidities and the prevalence of
major ARDS risk factors [30].
Hence, studying patients with ALI is a challenge
because the syndrome is the end result of an almost
infinite variety of scenarios. These range from young fit
patients with severe pneumonia or thoracic trauma to
older patients who fail to recover from routine proce-
dures, suffer complications, require respiratory support
because of a combination of a chronic cardio-respiratory
condition and hospital-acquired pneumonia, and ulti-
mately develop ARDS on a ventilator. As a consequence,
the water is muddied both by heterogeneity in the host
and in the risk factors, and by the variety of other co-
incident processes. Furthermore, it is often difficult to
define precisely when the syndrome started, which may
have a dramatic effect on measured variables in cases
where the condition changes rapidly. Finally, variable
management regimens may contribute to patient hetero-
geneity, both in the face of clear evidence (for example,
poor adherence to low tidal volume ventilation) [31]
and where evidence is lacking (for example, in the use
of adjuncts to respiratory support like prone positioning,
inhaled nitric oxide and high frequency oscillation).
Conversely, critically ill patients are closely monitored,
physiological data are electronically stored and their
Table 1 NAECC definition of Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS)[1]
Timing Oxygenation Chest Radiograph Exclusion of cardiogenic pulmonary oedema
ALI
ARDS
Acute PaO2/FiO2 ≤ 300 mmHg
or 40 kPa
PaO2/FiO2 ≤ 200 mmHg
or 27 kPa
Bilateral opacities consistent with
pulmonary oedema
PAOP ≤ 18 mmHg if measured or no clinical evidence of left
atrial hypertension
PaO2/FiO2, arterial partial pressure of oxygen/inspired oxygen fraction; PAOP, pulmonary artery occlusion pressure
Inflammation
Coagulation
Altered cell function
Tissue injury
Fibrogenesis/ Repair
 
 
 
 
 
Precipitating cause or risk factors for ALI 
 
 
 
 
 
 
 
Genetic factors
Comorbidities
Infection
VALI
TRALI
Fluid overload
Figure 1 Process-based pathogenesis of ALI. Traditional causes
of or risk factors for ALI maybe contributed to in certain patients by
hospital-acquired harm (red) and modified in their potency for
causing ALI by multiple patient’s susceptibility (blue). Depending on
the balance of these factors the processes that determine the
natural history of ALI are initiated in the lung.
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clinical condition may paradoxically render them more
amenable to undergoing invasive procedures.
Why invest in biomarkers for ALI?
Biomarkers are potentially useful as guides to clinical
management and as research tools. In the clinical setting
there is a high premium on biomarker data being easily
and safely obtained within a timeframe that is relevant
to the disease process (Table 2). For example, an indica-
tor of poor prognosis that may encourage referral to a
specialist center would need to be available within
hours, whereas a marker of ventilator-associated lung
injury (VALI) that was being used to fine-tune ventilator
settings would have to be “turned around” within min-
utes. No biomarkers that are currently available have
penetrated routine clinical practice with the possible
exception of the use of procalcitonin (PCT) to diagnose
sepsis in critically ill patients and to guide their antibio-
tic therapy [32]. Sepsis syndromes commonly both cause
and complicate ALI; ventilator associated pneumonia in
particular frequently exacerbates ALI causing diagnostic
difficulty. Procalcitonin levels correlated with severe sep-
sis and bacteraemia [33], but did not consistently differ-
entiate survivors from non-survivors [34]. A PCT-based
algorithm guiding initiation and duration of antibiotic
therapy in critically ill patients with suspected bacterial
infection was associated with a 23% relative reduction in
antibiotic exposure with no significant increase in mor-
tality [32]. Aside from this role in limiting antibiotic
exposure, a recent review of the role of PCT in diagnos-
ing ventilator associated pneumonia concluded that the
biomarker showed good specificity but low sensitivity
[35].
Clinical research in ALI has used biomarkers as surro-
gate outcomes for early Phase 2 studies and may in the
future be valuable in categorizing patients into sub-
groups that are predicted to be most likely to benefit
from particular interventions. For example, in the sin-
gle-centre BALTI 1 study 40 patients with ALI were
enrolled to demonstrate the ability of seven days of
treatment with intravenous salbutamol to decrease
extravascular lung water measured by the single indica-
tor transpulmonary thermodilution method (PiCCO,
Pulsion Medical Systems, Munich, Germany) [36]. The
resolution of pulmonary edema is central to recovery
from ALI as it entails defervescence of air space inflam-
mation and restoration of a functioning alveolar-capil-
lary membrane. Accordingly, elevated extravascular lung
water measured using this technique early in the course
of ALI/ARDS, particularly if indexed to predicted body
weight, was associated with a poor outcome [37-39].
The initial ratio of PaO2/FiO2 was reported to be lower
in non-survivors [9,40-42] and predicted mortality in
univariate analyses [9,40,42]. In addition, in one large
cohort study, PaO2/FiO2 ratio was an independent pre-
dictor of mortality [42]. However, this variable does not
take into account the mode or even presence of
mechanical ventilation and apart from measurements at
the extremes of the spectrum, it is generally not consid-
ered to be a robust predictor of outcome in ALI. Hence,
the use of a surrogate rather than a clinical end-point,
such as ventilator-free days or intensive care unit length
of stay, decreased the recruitment target to what was
achievable for a single center. However, in hindsight it
is arguable whether this positive result then justified the
investment in two Phase 3 large multicenter trials,
which failed to show a survival benefit from using both
inhaled and intravenous formulations of short-acting
beta agonists [25].
The use of biomarkers to refine patient populations,
such that clinical trials will be most likely to provide a
definitive answer requiring the fewest patients, is parti-
cularly appealing for application to research involving
patients with a heterogeneous syndrome like ALI. This
could be beneficial by helping to characterize either a
group of patients with a high mortality where mortality
is the primary outcome measure, or by identifying
patients in whom a pathological process, which is tar-
geted by an intervention, is particularly prominent.
Characteristics of ideal biomarkers for ALI
Proposed criteria for characterizing ideal biomarkers for
ALI, most of which are self-explanatory are listed in
Table 2. It has been argued that biomarkers should
inform or, at least, relate to the disease pathogenesis
[43]. We disagree for philosophical reasons. Why con-
fuse elucidating mechanisms with the pragmatic busi-
ness of identifying biomarkers? We prefer as wide a
definition as possible; for example, the electrocardio-
graph has been one of the most useful biomarkers in
medicine but not much can be learned about the patho-
genesis of myocardial infarction through its study.
The current definition of ALI/ARDS is such that bio-
markers of the established syndrome are largely redun-
dant. An exception would be a biomarker that was
specific to the pathological process described as diffuse
alveolar damage. That is, a biomarker that could exclude
patients from studies who fulfilled the diagnostic criteria
but who essentially have a distinct disease, which may
Table 2 Proposed characteristics of an ideal biomarker
for acute lung injury
Measurement is safe and feasible in the critically ill
Sensitive, reproducible and specific
Timely
Modified by an effective intervention to change the target outcome
of interest
Proudfoot et al. BMC Medicine 2011, 9:132
http://www.biomedcentral.com/1741-7015/9/132
Page 3 of 8
have a different natural history and specific treatment,
for example, cardiogenic pulmonary oedema, eosinophi-
lic pneumonia and pulmonary embolism. Most studies
have attempted to correlate selected biomarkers with
disease severity or death, which is potentially useful
both clinically to help target resources and more expen-
sive or invasive management strategies, and in helping
to power research studies using mortality as the primary
outcome.
We propose that the use of biomarkers in a complex
syndrome like ALI is most likely to be effective when
they are specific to an individual component or process
that can be manipulated. One productive approach has
been to measure plasma and BAL fluid levels of media-
tors as a reflection of systemic and pulmonary inflam-
mation respectively. In samples from large multicenter
trials elevated levels of mediators, like soluble tumor
necrosis factor-alpha receptors (sTNFR) 1 and 2 [44],
soluble intercellular adhesion molecule-1 [45], and inter-
leukin (IL)-6 [23] were associated with adverse out-
comes in patients with ALI. The limitations of this
strategy are that these mediators have multiple effects,
have no specificity to the lung and there is no convin-
cing evidence that manipulating the inflammatory
response benefits patients with ALI. Partly because of
the realization that VALI plays a major part in the
pathogenesis of ALI and, as a result, many large studies
have been performed examining the effects of ventilator
strategies, a lot has been learned about the responses of
popular biomarkers in patients undergoing protective
and standard ventilation [6]. Hence, circulating media-
tors of inflammation (sTNFR [45], IL-6, -8 and -10
[46]), indicators of epithelial cell injury (soluble
advanced glycation end-product receptors (sRAGE)) [47]
and surfactant protein-D [48]) and components of the
coagulation system (protein-C and plasminogen activa-
tor inhibitor-1 [49]) have all been promoted as biomar-
kers of VALI. However, because the proposed
mechanism, whereby VALI kills patients through the
exacerbation of local injury and inflammation, the med-
iators of which then leak into the systemic circulation
causing multiple organ dysfunction [50], it would be
surprising if there was not considerable overlap between
markers of VALI, tissue injury, inflammation and a poor
prognosis. In other words, these biomarkers inevitably
lack specificity for individual processes or outcomes.
More recently the power of combining clinical para-
meters with a panel of traditional biomarkers to predict
mortality in patients with ALI using a variety of statisti-
cal techniques has been examined in the large datasets
and sample stores resulting from ARDS Network studies
[51,52]. In one of these studies [52], the six clinical pre-
dictors were: age, the underlying cause, APACHE III
score, plateau pressure, number of organ failures, and
alveolar-arterial difference in the partial pressure of oxy-
gen measured at enrollment prior to randomization.
Eight biomarkers were measured in baseline plasma
samples from enrolled patients that reflected endothelial
and epithelial injury, inflammation and coagulation. A
“reduced model”, including just the APACHE III score,
age, SP-D, and IL-8, performed almost as well as that
which included all parameters and biomarkers. However,
the additional predictive value of the plasma biomarkers
added to the clinical predictors alone was modest; thus,
further work will be needed to test the value of these
biomarkers over clinical predictors alone. Furthermore,
while the inclusion of biomarker data into a model
improved the accuracy of mortality prediction, the pre-
dicted risk of death for the patients who ultimately died
remained lower than 50%, suggesting that important
contributors to mortality may not have been accounted
for by the model [51].
Model systems for biomarker development
An alternative approach to examining clinical samples is
to test the validity of existing or novel candidate bio-
markers using models systems, in which the signal-to-
noise ratio is likely to be more favorable and the time
course of the biomarker’s response can be more pre-
cisely determined (Figure 2). For this purpose, we
believe that human models are likely to be more useful
than animal models, despite the undoubted contribution
of the latter to our understanding of the syndrome’s
pathogenesis [53,54]. For example, at the most basic
level comparative proteomic analysis between BAL fluid
from a patient and a mouse model of ALI identified
only 21 homologous proteins [55].
For an example of a human model of ALI, one lung
ventilation (OLV), a technique required to facilitate lung
resection surgery, has been exploited to investigate
potential biomarkers of VALI [56,57]. One-lung ventila-
tion may be a useful model of VALI because it is asso-
ciated with a smaller lung volume available for
ventilation, localized lung collapse or atelectasis and
impaired oxygenation, resulting in exposure of the venti-
lated lung to volutrauma, repeated opening of collapsed
airspaces (atelectotrauma), and a high inspired oxygen
concentration. High tidal volume and airway pressure
during OLV correlated with the development of ALI in
patients undergoing lung resection {Fernandez-Perez,
2009 #1309 [58]; Licker, 2003 #38; Jeon, 2009 #532} and
the incidence of ALI after lung resection over a five-year
period was lower, compared to an historical control
group, after introduction of a protective OLV protocol
[59]. In small prospective studies the use of low tidal
volume OLV was associated with reduced biomarkers of
pulmonary and systemic inflammation {Michelet, 2006
#4882; [60]} Finally, in an observational prospective
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study of 30 patients, exhaled breath condensate pH was
reduced within minutes of starting OLV suggesting that
it may represent a robust and direct means of sampling
the milieu of the lung. While, in the clinical setting the
effect on exhaled breath condensate pH of changing
ventilator settings may be drowned by “noise” from co-
incident inflammatory processes in the lung, it may hold
promise as a non-invasive real-time biomarker of VALI,
despite the fact that the mechanism by which exhaled
breath condensate acidification is poorly understood
(Figure 2).
Future directions
Despite analyzing samples from large well-designed
trials, there is no biomarker in current use that posi-
tively identifies patients with the classical histopathologi-
cal appearances of diffuse alveolar damage, that predicts
a poor outcome or that specifically identifies a patholo-
gical process [61].
We propose that future biomarker development be
driven by novel therapies and support modalities. Bio-
markers potentially combined with physiological and
genomic data should be used to identify patient groups
BAL
Breath
Imaging
Physiology
Inflammation
Cell injury
SIRS
MODS
Organ 
dysfunction
Death
6 ml/kg pbw> 10 ml/kg pbw
Figure 2 ALI biomarkers: Ventilator Induced Lung Injury experimental models and observational clinical studies. High tidal volume
ventilation (tidal volume in excess of 10 ml/kg predicted body weight) may be used to induce lung injury in experimental models (left) but,
through the overspill of inflammatory mediators into the circulation (biotrauma), multiple-organ dysfunction may follow. Biomarkers may be
assayed directly from the lungs (black), from the circulation (red) or as indices of dysfunction related to other organs (green). In clinical studies
(right), injured lungs are susceptible to damage even when gold standard mechanical ventilation (tidal volume 6 ml/kg predicted body weight)
is used. However, in the presence of existing lung injury several processes are likely to be concurrent, both affecting the lungs directly
(inflammation, tissue injury, coagulation, fibrosis) and indirectly from other affected organs (sepsis). Hence, the relationship between any
biomarker and ventilator settings is likely to be obscured by multiple unknowns. BAL bronchoalveolar lavage, SIRS systemic inflammatory
response syndrome, MODS multiple organ dysfunction syndrome.
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for research studies and individuals who are most likely
to gain from targeted therapies. For example, novel
extra-corporeal carbon dioxide removal (ECCO2R) sys-
tems that will make these techniques safer, cheaper and
more readily available should stimulate the search for
novel biomarkers for VALI. The demonstration that
gold standard low tidal volume protective ventilation
was associated with signs of over-distension on CT
scanning, elevated plasma markers of inflammation and
a plateau airway pressure greater than 28 cmH2O in
approximately a third of patients with ARDS provided a
readily identifiable population on which the effectiveness
of novel ECCO2R devices could be tested [62]. In a sub-
sequent study, a group of patients with ARDS was iden-
tified by their having a plateau airway pressure greater
than 28 cmH2O and in whom low tidal volume ventila-
tion was presumed to be causing significant VALI. For
these patients a novel ECCO2R device (DeCap, Hemo-
dec, Salerno, Italy) enabled the research team to
decrease tidal volume, further targeting a plateau airway
pressure of less than 25 cmH2O, which was associated
with a lower radiographic index of lung injury and
lower levels of lung derived inflammatory cytokines [63].
Targeting component processes of ALI other than
inflammation, tissue injury and VALI should be devel-
oped and incentive for this will be greatly increased as
novel therapeutics are introduced (Figure 1). We believe
that advances in the understanding and treatment of
pulmonary fibrosis combined with the relative chronicity
of this process complicating ALI, which leads to patients
with a low pulmonary compliance struggling to wean
from ventilatory support, make this process suitable for
targeted intervention. For example, the significance of
the epithelial cell integrin alpha-v beta-6 in activating
transforming growth factor beta-1 (TGFb-1) both in the
evolution of ALI and repair by fibrosis has only recently
been appreciated [64,65]. Supposing an effective means
of targeting this pathway existed, how could the decision
to administer a novel therapy be informed using bio-
markers? Patients who are susceptible to or have over-
activity of this pathway may be identified using a geno-
mic approach or by identifying a biomarker that is
either specific to this process or a damaging fibrotic
response. Indeed, the feasibility of this approach has
been illustrated by the observation that elevated levels
of procollagen peptide III in lavage fluid from patients
on Day 3 of ARDS were independent risk factors for
mortality [66]. This so-called personalized approach has
been pioneered in other chronic lung diseases but the
principles are theoretically applicable to ALI [67].
Conclusions
Biomarker development for patients with ALI is an
essential component of progress in translational
medicine in this challenging area. Potential pitfalls on
the road to successfully carrying out translational medi-
cine to help patients with ALI include:
1. the heterogeneity of cases (ALI is a syndrome
resulting from any cause of acute lung failure),
2. the large iatrogenic contribution to pathogenesis,
rendering standardization of care crucial,
3. the gas exchange surface of the lung is relatively
inaccessible to investigation and indispensible, so
that pathogenic process are not well understood,
and
4. the timeframes of the condition are short, such
that windows for intervention may close in the time
that it takes to analyse samples and process data.
Biomarkers should be sensitive and specific indicators
of clinically important processes and should change in a
relevant timeframe to affect recruitment to trials or clin-
ical management. They do not necessarily need to
reflect pathogenic processes. Combining biomarkers
with physiological and other data may add predictive
power and stimulate the development of important aids
to research and therapy. While biomarkers have not yet
had a major role in the management of ALI and the
development of novel therapies, it is possible and even
likely that biomarkers will be developed that will help to
target an increasing arsenal of disease modifying thera-
pies in the future.
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